Sta r max

Manufactured by Diagnostica Stago

Sourced in France

The STA-R Max is an automated hemostasis analyzer designed for routine and specialized coagulation testing. It offers high-throughput capabilities and can perform a wide range of coagulation assays. The STA-R Max is intended for use in clinical laboratories to support the diagnosis and monitoring of hemostatic disorders.

Automatically generated - may contain errors

Lab products found in correlation

Cobas 601, by Roche (4 mentions) Xn 10, by Sysmex (4 mentions) Cs 5100, by Sysmex (2 mentions) Cs 2400, by Sysmex (1 mentions) Sta stachrom at 3, by Diagnostica Stago (1 mentions) Magnetic luminex assay, by Bio-Techne (1 mentions) Automated clinical chemistry analyzer, by Roche (1 mentions) Sodium citrate, by BD (1 mentions) Sta r evolution, by Diagnostica Stago (1 mentions) Sta compact max, by Diagnostica Stago (1 mentions) Cobas c702, by Roche (1 mentions) Actin fs, by Siemens (1 mentions) Cs2100, by Siemens (1 mentions)

Spelling variants of this product

STA-R Max analyzer (8 citations) STA-R MAX coagulation analyzer (5 citations) STA-R (4 citations)

16 protocols using sta r max

Assessing Factor V and Protein C Levels

Check if the same lab product or an alternative is used in the 5 most similar protocols

STA-Deficient V (Diagnostica Stago, Asnieres, France) was used as the reagent, and STA R MAX (Diagnostica Stago, Asnieres, France) was used as the equipment for the factor V test. The test was performed using the coagulation method. We measured the activity of factor V in plasma using the factor V-deficient plasma of the reagent.
STA – Stachrome protein C (Diagnostica Stago, Asnieres, France) was used as the reagent, and STAR MAX (Diagnostica Stago, Asnieres, France) was used as the equipment for the protein C test. Both tests were commercialized. STA – Unical Corrector (Diagnostica Stago, Asnieres, France) activated using the correction curve was expressed as the functional protein C level, using the calibration curve % material.
Quality control was performed using the commercially available STA – System Control N+P (Diagnostica Stago, Asnieres, France) substance for each test. All tests were performed according to the manufacturer's instructions, and the results were analyzed retrospectively.

Na M.J, & Kim J.K. (2024). Characteristics of factor V and protein C based on results from Korean testing centers. Blood Coagulation & Fibrinolysis, 35(4), 173-179.

+ Open protocol

+ Expand

Heparin Anti-FXa Assay Protocols

Check if the same lab product or an alternative is used in the 5 most similar protocols

Each heparin anti-FXa assay was used according to the associated manufacturer’s instrument: Diagnostica Stago reagent A with STA-R Max (Diagnostica Stago, Asnières, France); IL-Werfen reagent B with ACL-Top 550 (IL Werfen, Le Pré St Gervais, France); Siemens reagent C with CS-5100 (an automated instrument from Sysmex, Kobe, Japan, and distributed by Siemens Healthineers, Aubervilliers, France); HYPHEN BioMed reagent D with the Sysmex CS-5100 instrument (Sysmex, Kobe, Japan); the BIOPHEN anti-FIIa and anti-Xa 2-stage assays were used with the CS-2400 instrument (Sysmex, Kobe, Japan). Reagents were used respecting strictly the recommended manufacturers’ protocols. HYPHEN BioMed reagents, proposed for multiplatform applications, were used with the CE marked protocols developed and validated for CS-5100. All assayed plasmas were tested undiluted (reagent B) or diluted, as claimed in the instructions for use for each assay. Plasma diluent was Owren Veronal Buffer (reagents A and C) or 0.15 M sodium chloride (reagent D).

Amiral J., Amiral C, & Dunois C. (2021). Optimization of Heparin Monitoring with Anti-FXa Assays and the Impact of Dextran Sulfate for Measuring All Drug Activity. Biomedicines, 9(6), 700.

+ Open protocol

+ Expand

Measuring AT, Fibrinogen, and α2M Levels

Check if the same lab product or an alternative is used in the 5 most similar protocols

AT, fibrinogen and α₂Macroglobulin (α₂M) levels were measured to perform TD analysis. AT was measured on the automated coagulation analyzer STA-R Max according to manufacturer specifications using STA^®-Stachrom ATIII kit (reagent and analyzer Diagnostica Stago, Asnières-sur-Seine, France). Functional fibrinogen levels were measured using the Clauss method with STA^®-Liquid Fib on STart (reagent and semi-automated analyzer Diagnostica Stago, Asnières-sur-Seine, France). Plasma α₂M levels were measured with an in-house chromogenic assay as previously described by Kremers et al. (14 (link)).

Carlo A., Yan Q., Ten Cate H., De Laat-Kremers R., De Laat B, & Ninivaggi M. (2022). Semi-automated thrombin dynamics applying the ST Genesia thrombin generation assay. Frontiers in Cardiovascular Medicine, 9, 912433.

+ Open protocol

+ Expand

Comprehensive Hematology and Coagulation Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols

A SYSMEX XN-10 instrument (Sysmex Corporation, Kobe, Japan) was used for testing the hematology parameters of the full blood count which included the red blood cell count (RBC), hemoglobin concentration (Hb), hematocrit (HCT), mean cell volume (MCV), mean cell hemoglobin (MCH), mean cell hemoglobin concentration (MCHC), red cell distribution width (RDW), reticulocyte count (RET), normoblast (NRBCs), total white blood cell count (WBC) and differential counts (lymphocyte, monocyte, eosinophils, basophil, neutrophil), platelet count (PLT), mean platelet volume (MPV) and platelet distribution width (PDW). For testing different coagulation factors (pro-coagulant clotting factors, and anticoagulant proteins) we used STAR Max (Diagnostica Stago, Marseille, France). Testing of the serum level of hematinics (iron, ferritin, vitamin B12, and folic acid) was performed using automated chemistry analyzer COBAS 601 (Roche Diagnostic, Basel, Switzerland). All laboratory equipment had passed calibration as per manufacturer instructions, in addition to quality control assessment as per College of American Pathology guidelines.

Bakr S., AlFattani A., Al-Nounou R., Bakshi N., Khogeer H., Alharbi M., Almousa N., Alomaim W., Aguilos A., Almashary M, & Owaidah T. (2022). Hematologic reference intervals for healthy adult Saudis in Riyadh. Annals of Saudi Medicine, 42(3), 191-203.

+ Open protocol

+ Expand

Comprehensive Hematologic and Coagulation Profiling

Check if the same lab product or an alternative is used in the 5 most similar protocols

Blood Samples comprising 10 cc of EDTA, 10 cc of Citrated blood (at 3.2%), and 5 cc sodium heparin were collected at admission, 3rd day, 7th day, and 14th day for those who stayed for up to 14 days. CBC and complete 5 parts differential were tested from the EDTA samples using an automated SYSMEX XN-10 instrument (Sysmex Corporation, Kobe, Japan). Serum creatinine and C reactive protein were measured using an automated chemistry analyzer COBAS 601 (Roche Diagnostics, Basel, Switzerland). ABO blood grouping was carried out via Diamed Gel card (Changsha Yingtai Instrument Co., Ltd).
The samples for the coagulation tests were centrifuged within two hours and aliquoted for testing different coagulation markers, including prothrombin time (PT), international normalization ratio (INR), activated thromboplastin time (APTT), D-dimer, FIB, AT, PC, PS, vWF Ag, and FVIII using STAR Max^® (Diagnostica Stago, Marseille, France).

Saleh M., Alkofide A., Alshammari A., Siddiqui K, & Owaidah T. (2021). Changes in Hematological, Clinical and Laboratory Parameters for Children with COVID-19: Single-Center Experience. Journal of Blood Medicine, 12, 819-826.

+ Open protocol

+ Expand

Measuring Plasma AT Levels

Check if the same lab product or an alternative is used in the 5 most similar protocols

Plasma AT levels were measured in 20,521 samples, at the Synapse Research Institute laboratories, Maastricht (the Netherlands), on the STA-R Max (Diagnostica Stago, France) using the STA-Stachrom AT III reagent according to the manufacturer recommendations. The analytical reporting range was 9%-160% and the intra- and inter-assay variation were 2.6% and 4.8%, respectively. The reference range for AT in the general population as reported in literature is 71–130% [18 (link)].

Iacoviello L., de Laat-Kremers R., Costanzo S., Yan Q., Di Castelnuovo A., van der Vorm L., De Curtis A., Ninivaggi M., Cerletti C., Donati M.B, & de Laat B. (2022). Low antithrombin levels are associated with low risk of cardiovascular death but are a risk factor for cancer mortality. PLoS ONE, 17(9), e0271663.

+ Open protocol

+ Expand

Characterizing COVID-19 Severity Markers

Check if the same lab product or an alternative is used in the 5 most similar protocols

Epidemiological characteristics, comorbidities, coagulation function markers on admission and disease severity, were obtained from patients' medical records. D-dimer were detected using a STA-R MAX coagulation analyzer and original reagents (Diagnostica Stago, Saint-Denis, France). The severity of COVID-19 was defined according to WHO clinical management guidance of COVID-19 [7 ]. Severe type was defined as followed: fever or suspected respiratory infection, plus one of respiratory rate > 30 breaths/min, severe respiratory distress, or SpO₂ < 90% on room air.

Yu H.H., Qin C., Chen M., Wang W, & Tian D.S. (2020). D-dimer level is associated with the severity of COVID-19. Thrombosis Research, 195, 219-225.

+ Open protocol

+ Expand

Comprehensive Blood Parameter Profiling

Check if the same lab product or an alternative is used in the 5 most similar protocols

Routine blood chemistry and hematologic parameters, including the blood count, aminotransferases, lactate dehydrogenase (LDH), glomerular filtration rate, and CRP were recorded. Hemostasis exploration was performed by measuring the PT, activated partial thromboplastin time, fibrinogen, D-dimer (STA-Liatest D-Di Plus), plasminogen, and plasminogen activator inhibitor-1 (PAI-1) activity (STA R Max, Diagnostica Stago, Asnières, France). The serum levels of interferon-γ–inducible protein 10 (IP-10) and interleukin-6 (IL-6) were quantified using the magnetic luminex assay (Bio-Techne, Minneapolis, MN).

Guervilly C., Bonifay A., Burtey S., Sabatier F., Cauchois R., Abdili E., Arnaud L., Lano G., Pietri L., Robert T., Velier M., Papazian L., Albanese J., Kaplanski G., Dignat-George F, & Lacroix R. (2021). Dissemination of extreme levels of extracellular vesicles: tissue factor activity in patients with severe COVID-19. Blood Advances, 5(3), 628-634.

+ Open protocol

+ Expand

SARS-CoV-2 Biomarker Monitoring Protocol

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

Real-time RT–PCR tests were performed to detect SARS-CoV-2 nucleic acid; the detailed protocols were described previously [32 (link)]. During hospitalization, serial monitoring of 30 laboratory biomarkers (Table S1) was conducted for each COVID-19 patient, and blood samples were collected at different time points when laboratory biomarkers were requested by physicians to monitor disease progression. Laboratory biomarkers, such as routine peripheral blood biomarkers, inflammatory biomarkers, coagulation biomarkers, serum biochemical biomarkers, and anti-SARS-CoV-2 IgG and IgM antibodies, were assessed during hospitalization. Peripheral blood was collected for routine blood tests using an automated hematology analyzer. Biochemical biomarkers such as albumin, alanine aminotransferase, aspartate aminotransferase, and creatinine were measured using a Roche automated clinical chemistry analyzer (Roche Diagnostics). Coagulation tests were conducted with a new coagulation analyzer, STAR Max® (Diagnostica Stago). Serum quantitative measurements of anti-SARS-CoV-2 IgM and IgG antibodies were conducted using commercial chemiluminescence kits of iFlash-SARS-CoV-2 IgM (Cat. No. C86095M) and iFlash-SARS-CoV-2 IgG (Cat. No. C86095G) from Shenzhen YHLO Biotech. Seroconversion was defined by the cutoff of IgG ≥ 10 AU/mL or IgM ≥ 10 AU/mL.

Jing X., Xu M., Song D., Yue T., Wang Y., Zhang P., Zhong Y., Zhang M., Lam T.T., Faria N.R., De Clercq E, & Li G. (2022). Association between inflammatory cytokines and anti-SARS-CoV-2 antibodies in hospitalized patients with COVID-19. Immunity & Ageing : I & A, 19, 12.

+ Open protocol

+ Expand

Enoxaparin Dosing Optimization in High-Risk Pregnancies

Check if the same lab product or an alternative is used in the 5 most similar protocols

Venous blood for anti-Xa measurement was collected in 3.2% sodium citrate (Becton-Dickinson, Oxford, the United Kingdom) at a mean ± standard deviation (SD) of 3.3 ± 0.4 h after the last enoxaparin injection. Anti-Xa analysis was performed on the STA-R Max^® automated coagulation analyzer (Diagnostica Stago, Asnières sur Seine, France). Serial peak anti-Xa levels were available in 52 (88.1%) high-risk pregnancies. With pregnancy progression, 10 (19.2%) required a dose adjustment in the second trimester and 13 (25.0%) in the third trimester to achieve the target range.

Schapkaitz E., Libhaber E., Gerber A., Rhemtula H., Zamparini J., Jacobson B.F, & Büller H.R. (2023). A Longitudinal Study of Thrombosis and Bleeding Outcomes With Thromboprophylaxis in Pregnant Women at Intermediate and High Risk of VTE. Clinical and Applied Thrombosis/Hemostasis, 29, 10760296231160748.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!